STOCKHOLM, June 14, 2022 /PRNewswire/ — Hemcheck has received an order from a medical technology company based in France which focuses on technology-assisted blood sampling. The order has a lower economic value but shows the potential for research and development. The prescription refers to the detection of hemolysis for diagnostic purposes.
– It’s very positive to have another client in a short time. We continue to work with a focus on marketing our products and hope to attract more customers as we see strong interest in our products, said Joen Averstad, CEO of Hemcheck.
For more information, contact:
Hemcheck Sweden AB (publisher)
Joen Averstad, CEO
Tel: +46 76 108 8191
Email: [email protected]
Hemcheck Sweden AB, founded in 2010, produces and markets a patented CE-marked concept for point-of-care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly after collection, identify hemolyzed blood samples in vacuum tubes and blood gas syringes. Hemolysis, i.e. the rupture of red blood cells, is the most common reason worldwide why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck’s objective is to contribute to the improvement of healthcare by offering user-friendly solutions for the detection of hemolyzed blood samples in direct connection with blood sampling near the patient. In doing so, Hemcheck can help increase patient safety, improve process efficiency and reduce costs. The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, [email protected], is the company’s certified advisor.
This information was brought to you by Cision http://news.cision.com